A Randomized Phase 2 Study of Long-Acting TransCon GH vs Daily GH in Childhood GH Deficiency.
- Resource Type
- Article
- Authors
- Chatelain, Pierre; Malievskiy, Oleg; Radziuk, Klaudziya; Senatorova, Ganna; Abdou, Magdy O; Vlachopapadopoulou, Elpis; Skorodok, Yulia; Peterkova, Valentina; Leff, Jonathan A; Beckert, Michael
- Source
- The Journal of Clinical Endocrinology & Metabolism; May 2017, Vol. 102 Issue: 5 p1673-1682, 10p
- Subject
- Language
- ISSN
- 0021972X; 19457197
TransCon Growth Hormone (GH) (Ascendis Pharma) is a long-acting recombinant sustained-release human GH prodrug in development for children with GH deficiency (GHD).